Evidence map›Paper›PMID 40802116›Full record

ArticleJournal of neuro-oncology2025

Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells.

Matthew Z Sun, Erick Contreras, Janet Treger, Marisa Imbroane, Joey Orpilla, Myungjun Ko, Jeremy Reynoso, Sara Khattab, Thomas J Lai, Jonathan E Tsang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Matthew Z SunUniversity of Texas Southwestern School of Medicine, 5323 Harry Hines Blvd Mail Ext Code: 8855, Dallas, TX, 75390, USA. Matthew.sun@utsouthwestern.edu.
Erick ContrerasUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Janet TregerUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Marisa ImbroaneUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Joey OrpillaUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Myungjun KoUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Jeremy ReynosoUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Sara KhattabUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Thomas J LaiUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Jonathan E TsangUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Jeremie VitteUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Marco GiovanniniUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Linda M LiauUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Robert PrinsUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA.
Richard G EversonUniversity of California Los Angeles, 300 Stein Plaza Driveway Suite 420, Los Angeles, CA, 90095, USA. REverson@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015NIH HHS NS079198NIH HHS P50CA211015 CEP
6 · The paper itself

Abstract

introductionMalignant meningiomas lack effective immunotherapeutic options. NY-ESO-1 is a potential immunotherapeutic target, because it is the most frequently expressed cancer-testis-antigen in meningiomas. We investigated the efficacy of T-Cell-Receptor-Transduced T-Cells (TCR-T) targeting NY-ESO-1 in vitro and in vivo in meningiomas.

methodsImmunohistochemistry was performed on Grade I-III meningioma specimens. Primary meningioma culture LB3750(Grade I) and immortalized cultures SF1335(Grade I) and CH157-HLA-A2.1(Grade III) were established and maintained in vitro. NY-ESO-1 TCR-T (HLA-A2.1 restricted) cells were co-cultured with primary and immortalized meningioma cells and assessed for real-time tumor killing in vitro. Immunodeficient NSG mice were intracranially implanted with CH157-HLA-A2.1 and SF1335 cells, treated with systemic adoptive cell transfer (ACT) of TCR-T, and assessed for overall survival in vivo.

resultsNY-ESO-1 expression correlated with tumor grade (n = 35; p < 0.01). High NY-ESO-1 nuclear expression predicted a worse progression-free-survival (p = 0.0167). CH157-HLA-A2.1 cells, with native high NY-ESO-1 expression, experienced > 60% and then nearly 100% cytolysis after co-culture with TCR-T for 10 and 24 h, respectively, compared with control T-cells (p < 0.0001). SF1335 and LB3750 cells, with low NY-ESO-1 expression, experienced 20% cytolysis after 24 h of co-culture with TCR-T compared to the control (p < 0.0001). Systemic ACT of TCR-T significantly increased the median overall survival in NSG mice bearing intracranial xenografts of CH157-HLA-A2.1 by 49% (p < 0.001).

conclusionsNY-ESO-1 TCR-T induces cytolysis in meningiomas in vitro, and its efficacy correlates with NY-ESO-1 expression. Systemic ACT results in significantly increased survival in vivo in high-grade meningioma. Therefore, targeting NY-ESO-1 may be a clinically feasible immunotherapeutic strategy for treating high-grade meningiomas.

Indexed as

Antigens, NeoplasmImmunotherapy, AdoptiveMembrane ProteinsMeningeal NeoplasmsMeningiomaReceptors, Antigen, T-CellT-LymphocytesAgedAnimalsCell Line, TumorCoculture TechniquesFemaleHumansMaleMiceMice, Inbred NODAntigens, NeoplasmCTAG1B protein, humanMembrane ProteinsReceptors, Antigen, T-CellMeningioma immunotherapyNY-ESO-1Systemic adoptive cell transferTCR-T

Identifiers

PMID40802116
PMCPMC13271259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.